The benefits of the application of commercial vaccine products for M. hyopneumoniae are well known and documented, and there is a body of evidence that supports it.

Commercial vaccines reduce clinical signs and lung lesions associated with infection, and improve production parameters, although colonization and infection cannot be prevented with vaccination.

Data shows that the use of vaccines decreases bacterial load at lung level, potentially by modulating the shedding or by inducing a controlled and uniform immune response in the host.

Multiple vaccination of sows and gilts has shown decreased pathogen transmission from the sow to the piglet or among gilt populations. Thus, for eradication program purposes, vaccination after confirmation of population exposure may be most advantageous.